HPN-424

N/A

Report date: 2026/03/19 16:47:10

Base Information

Drug NameHPN-424

Drug Alias NamePSMA/CD3-specific TriTACHPN-424

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Trispecific monoclonal antibodyBiologics > T cell engagers

Mechanisms of ActionAnti-PSMAAnti-CD3

TargetsProstate-Specific Membrane AntigenT cell surface glycoprotein CD3

Therapy Area/IndicationsProstatic Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited StatesUnited Kingdom

CombinationsNo

Global Highest StatusDiscontinued (Phase 2 Clinical)

Highest Status in ChinaN/A

Originator CompaniesHarpoon Therapeutics

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesHarpoon Therapeutics

Active IndicationsN/A

Inactive IndicationsProstatic Neoplasms

Other Information

ATC CodeN/A